Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2000 Giugno;44(2) > The Quarterly Journal of Nuclear Medicine 2000 Giugno;44(2):186-90

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2000 Giugno;44(2):186-90

ECONOMICS OF NUCLEAR MEDICINE
Guest Editor: Gambhir S. S. 

Utility evaluations for Markov states of lung cancer for PET-based disease management

Papatheofanis F. J.

From the Department of Radiology The Advanced Medical Technology Assessment and Policy Program UCSD School of Medicine, San Diego, CA, USA

Background. Utilities for the ­health out­comes ­states (Markov ­states) of non-­small ­cell ­lung car­ci­no­ma (NSCLC) ­should be meas­ured to eval­u­ate man­age­ment ­options for ­patients ­because ­patients are key par­tic­i­pants in the pro­cess of ­care, and ­their assess­ment of diag­nos­tic and ther­a­peu­tic val­ue in the ­options pre­sent­ed to ­them ulti­mate­ly ­impacts ­their net ­health out­comes. This inves­ti­ga­tion ­sought to meas­ure util­ities for ­stage-depen­dent out­comes ­states of ­NSCLC.
Methods. Persons (n=23) ­with sus­pect­ed ­NSCLC ­based on phys­i­cal find­ings and com­put­ed tomog­ra­phy com­plet­ed a ­short util­ities sur­vey. Utility val­u­a­tions ­were ­obtained accord­ing to sever­ity of mor­bid­ity and var­ied con­sid­er­ably. Respondents rat­ed ­these ­health ­states accord­ing to accu­ra­cy meas­ures for 18flu­rod­e­ox­y­glu­cose (18FDG) posi­tron emis­sion tomog­ra­phy (PET) imag­ing and med­i­as­ti­nos­co­py.
Results. The ­results dem­on­strate ­that ­stage-depen­dent mor­bid­ity is an impor­tant con­sid­er­a­tion for ­patients ­with ­NSCLC and ­should be includ­ed in any deci­sion anal­y­sis regard­ing the eval­u­a­tion or treat­ment of ­NSCLC. Respondents val­ued the qual­ity of infor­ma­tion ­obtained ­from non-inva­sive PET and inva­sive med­i­as­ti­nos­co­py com­par­ably. The util­ities ­obtained ­from ­this inves­ti­ga­tion are use­ful in clin­i­cal deci­sion-mak­ing ­based on Markov pro­cess­es ­because ­they pro­vide an ­initial esti­ma­tion of util­ity assess­ment for 18FDG-­based diag­nos­tic eval­u­a­tion of ­lung can­cer.
Conclusions. Consequently, ­these util­ities ­will be use­ful in ­future deci­sion anal­y­ses ­that ­require ­patient pref­er­ence in the assign­ment of the val­u­a­tion of deci­sion ­options (branch­es).

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina